Apellis Pharmaceuticals, Inc. (APLS) Form 8-K — May 4, 2026
On April 28, 2026, Apellis Pharmaceuticals amended and restated its Executive Separation Benefits and Retention Plan in connection with its pending merger agreement with Biogen Inc. The amendments specify that unvested rights to payments for converted options and RSU awards will accelerate and vest in full if a participant is terminated without cause or resigns for good reason before the closing date. Additionally, the company removed a provision in the definition of 'Good Reason' that excluded changes in scope solely resulting from the company becoming a subsidiary of another corporation. This change applies specifically to C-Level Officers, including named executive officers.
Price after filing
Close on the filing date to close N calendar days later (from $40.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.